How well do coverage surveys and programmatically reported mass drug administration coverage match? Results from 214 mass drug administration campaigns in 15 countries, 2008–2017
BMJ Global Health2023Vol. 8(5), pp. e011193–e011193
Citations Over TimeTop 10% of 2023 papers
Kathryn L. Zoerhoff, Pamela Sabina Mbabazi, Katherine Gass, John D. Kraemer, Brian Fuller, Lynsey Blair, Roland Bougma, Aboulaye Meïté, Nebiyu Negussu, Bizuayehu Gashaw, Scott D. Nash, Nana‐Kwadwo Biritwum, Jean Frantz Lemoine, Helena Ullyartha Pangaribuan, Eksi Wijayanti, Karsor Kollie, Clara Fabienne Rasoamanamihaja, Lazarus Juziwelo, Square Mkwanda, Pradip Rimal, Issa Gnandou, Bocar Diop, Améyo M. Dorkenoo, Rachel N. Bronzan, Edridah M. Tukahebwa, Fatima Kabole, Violetta Yevstigneyeva, Donal Bisanzio, Lauren Courtney, Joseph B. Koroma, Egide Endayishimye, Richard Reithinger, Margaret Baker, Fiona Fleming
Abstract
Programme managers must grapple with making decisions based on imperfect information, balancing needs for accuracy with cost and available capacity. The study shows that for many of the MDAs surveyed, based on the concordance with respect to reaching the minimum coverage thresholds, the routinely reported data were accurate enough to make programmatic decisions. Where coverage surveys do show a need to improve accuracy of routinely reported results, NTD programme managers should use various tools and approaches to strengthen data quality in order to use data for decision-making to achieve NTD control and elimination goals.
Related Papers
- → Innovative Approaches to Census-Taking: Overview of the 2011 Census Round in Europe(2014)9 cited
- → The U.S. decennial census(1994)2 cited
- The Census of Ireland, 1821-1911: General Reports and Extracts(1998)
- → Background to the 1950 censuses of population(1956)
- → Editor's Corner(2020)